Skip to main content

Advertisement

Table 2 Association of CD44 and CD24 with clinicopathological variables in 69 SGMN patients

From: CD44/CD24 immunophenotypes on clinicopathologic features of salivary glands malignant neoplasms

  CD44 CD24
+ - p + - p
Gender Male 19 (13.0%) 9 (13.0%) 0.330 6 (8.7%) 22 (31.9%) 0.330
  Female 31 (44.9%) 10 (14.5%)   12 (17.4%) 29 (42.0%)  
Age ≤ 60 30 (43.5%) 11 (15.9%) 0.543 10 (14.5%) 31 (44.9%) 0.453
  > 60 20 (29.0%) 8 (11.6%)   8 (11.6%) 20 (29.0%)  
Smoking intake Yes 15 (21.7%) 8 (11.6%) 0.250 5 (7.2%) 18 (26.1%) 0.392
  No 35 (50.7%) 11 (15.9%)   13 (18.8%) 33 (47.8%)  
Alcohol intake Yes 9 (13.0%) 5 (7.2%) 0.324 5 (7.2%) 9 (13.0%) 0.275
  No 41 (59.4%) 14 (20.3%)   13 (18.8%) 42 (60.9%)  
PLSa Majorb 34 (49.3%) 8 (11.6%) 0.046 11 (15.9%) 31 (44.9%) 0.605
  Minorc 16 (23.2%) 11 (15.9%)   7 (10.1%) 20 (29.0%)  
Tumor size T1/T2 28 (40.6%) 14 (20.3%) 0.142 7 (10.1%) 35 (50.7%) 0.027
  T3/T4 22 (31.9%) 5 (7.2%)   11 (15.9%) 16 (23.2%)  
Clinical Stage I / II 19 (27.5%) 6 (8.7%) 0.419 2 (2.9%) 23 (33.3%) 0.008
  III / VI 31 (44.9%) 13 (18.8%)   16 (23.2%) 28 (40.6%)  
Treatment Surgery 14 (20.3%) 5 (7.2%) 0.572 4 (5.8%) 15 (21.7%) 0.398
  Sur. Adj. T.d 36 (52.2%) 14 (20.3%)   14 (20.3%) 36 (52.2%)  
Metastasis No 32 (46.4%) 11 (15.9%) 0.421 10 (14.5%) 33 (47.8%) 0.339
  Yes 18 (26.1%) 8 (11.6%)   8 (11.6%) 18 (26.1%)  
loco-regional No 33 (47.8%) 12 (17.4%) 0.519 10 (14.5%) 35 (50.7%) 0.236
recurrence Yes 17 (24.6%) 7 (10.1%)   8 (11.6%) 16 (23.2%)  
Lymph node Negative 43 (62.3%) 15 (21.7%) 0.352 10 (14.5%) 48 (69.6%) 0.001
  Positive 7 (10.1%) 4 (5.8%)   8 (11.6%) 3 (4.3%)  
Death No 36 (52.2%) 12 (17.4%) 0.332 14 (20.3%) 34 (49.3%) 0.285
  Yes 14 (20.3%) 7 (10.1%)   4 (5.8%) 17 (24.6%)  
CD24 Negative 36 (52.2%) 15 (21.7%)     0.398
  Positive 14 (20.3%) 4 (5.8%)     
CD44 Negative     4 (5.8%) 15 (21.7%) 0.398
  Positive     14 (20.3%) 36 (52.2%)  
  1. a PLS: Primary Lesion Site; bMajor: Major Salivary Glands ( Parotid Gland/Submandibular Gland/Sublingual Gland); cMinor; Minor Salivary Glands; dSur. Adj. T.: Surgery with adjuvant therapy. Statistically significant difference (<0.05) by Fisher’s exact test (two variables) or χ2 (three or more variables) tests.